Phase 3 topline
Primary completion of A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
ARGX · ARGENX SE · efgartigimod PH20 SC · Primary Immune Thrombocytopenia
Sources and detail
- Float
- No public float has been reported at a usable date.
- Stake
- Research for this company needs an account. The sample companies are fully interactive without one.
- Runway vs event
- Cash or burn is missing, so no runway verdict is made.
- Financing
- No financing filing in the period covered.
- Specialist holders
- No specialist 13F quarter has been read for this issuer.
- Insider net 90d
- No open-market insider transaction was filed in the window.
What happened
Ahead of its window
The stated window has not opened yet.
Sources (1)
- ClinicalTrials.gov · NCT04812925
clinicaltrials gov · published 2026-01-12 · retrieved 2026-09-21
“primaryCompletionDateStruct: {"date": "2026-10-01", "type": null}”
Research
This event is not joined to a researched indication.
Research date unknown
Market
Market linking is switched off.
Quotes elsewhere
This desk holds no price. These go to the venues that publish one.
What counts as each outcome
Resolved by the sponsor's topline disclosure of the trial's primary endpoint: met with statistical significance is success; missed is failure; co-primary endpoints split, or significance reached only in a pre-specified subgroup, is mixed.
Missing inputs
- issuer_facts: not collected
- public_float_usd: not collected
- shares_outstanding: not collected
- cash_and_investments: not collected
- operating_cash_flow: not collected
- quarterly_burn: not collected
- runway_quarters: not collected
Event row last changed 2026-09-21 · filing signals evaluated 2026-09-21
What changed on this event
- — · created · event · — → Primary completion of A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia · clinicaltrials_gov-candidate
- — · status · review_state · pending → published · government-source
This is a dated event and its evidence, not a forecast of its outcome. No price, implied move or market probability is collected or shown anywhere on this page.
